UniProtKB/Swiss-Prot Q13546: Variant p.Ala438Val

Receptor-interacting serine/threonine-protein kinase 1
Gene: RIPK1
Feedback?

Variant information Variant position:

438 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Alanine (A) to Valine (V) at position 438 (A438V, p.Ala438Val). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from small size and hydrophobic (A) to medium size and hydrophobic (V) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Other resources:

Links to websites of interest for the variant.

Variant rs3173519 [ dbSNP | Ensembl ]

Sequence information Variant position:

438 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

671 The length of the canonical sequence.
Location on the sequence:

DPFAQQRPYENFQNTEGKGT A YSSAASHGNAVHQPSGLTSQ The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         DPFAQQRPYENFQNTEGKGTAYSSAASHGNAVHQPSGLTSQ

Mouse                         DPFAQQRARENIKSAGARGHSDPSTTSRGIAVQQLSWPATQ

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 671	Receptor-interacting serine/threonine-protein kinase 1
Region	290 – 582	Interaction with SQSTM1
Region	389 – 458	Disordered
Compositional bias	423 – 458	Polar residues

Literature citations
TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex.
Hsu H.; Huang J.; Shu H.-B.; Baichwal V.R.; Goeddel D.V.;
Immunity 4:387-396(1996)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1); CATALYTIC ACTIVITY; AUTOPHOSPHORYLATION; MUTAGENESIS OF LYS-45; INTERACTION WITH TRADD; TRAF1; TRAF2 AND TRAF3; VARIANT VAL-438; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
The MGC Project Team;
Genome Res. 14:2121-2127(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1); VARIANT VAL-438; RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death.
Stanger B.Z.; Leder P.; Lee T.-H.; Kim E.; Seed B.;
Cell 81:513-523(1995)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 300-671; VARIANT VAL-438;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.